Faster and easier antibody screening and characterization

The development of potent and selective monoclonal antibodies (MAbs), or biotherapeutics, is currently a new challenge in the pharmaceutical industry's drug discovery process. This quest for better drugs concerns a wide range of diseases, including autoimmunity and inflammation, cancer, organ transplants, cardiovascular, infectious and ophthalmologic diseases. To meet this need, Cisbio Bioassays has developed new assay kits and tools for the screening and characterization of biotherapeutics, using the robustness and the flexibility of HTRF® technology.